The Filing Desk

Celldex Therapeutics

CLDX · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

CLDX · Last close · November 13, 2026
$28.83
Value Celldex Therapeutics yourself

Celldex Therapeutics' revenue fell 78.0% to $2 million in fiscal 2025. Its operating margin was −18,599.8%, down from −2,778.9% a year earlier. Free cash flow was −$214 million. The diluted share count rose 3.1%.

Celldex Therapeutics, Inc. Latest fiscal year ended December 31, 2025 10-K filed February 25, 2026 · 0001104659-26-019652 Updated
Revenue
$2M
78.0%
Operating margin
−18,599.8%
15820.9 pts
Net income
−$259M
 
Free cash flow
−$214M
 
Return on equity
−40.6%
13.8 pts
Market cap
$2.3B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Celldex Therapeutics does

Celldex Therapeutics is a biotechnology company developing antibody drugs. It has no product on the market. Its work centers on mast cells, immune cells involved in allergic and inflammatory reactions, and it targets diseases where current treatments fall short.

Its lead candidate, barzolvolimab, is an antibody that blocks a receptor called KIT on mast cells. It is being tested in chronic spontaneous urticaria, a long-lasting itchy skin condition with hives, where Celldex says enrollment is complete in its Phase 3 studies and it expects topline data in the fourth quarter of 2026. It also began a Phase 3 study in cold urticaria and symptomatic dermographism in December 2025.

Celldex has no product revenue and says it will need to raise capital to run its business, including to develop, make and sell its drug candidates.

Its biggest risks, as it describes them

  • It has no product revenue and will need to raise capital.
  • It expects losses and may never be profitable.
  • Its drug candidates need regulatory approval, which can be slow, limited or denied.
  • Success in early trials does not ensure success in later ones.
  • Slow patient enrollment or serious side effects could delay or stop testing.
From Celldex Therapeutics's annual report on Form 10-K, filed February 25, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Celldex Therapeutics lost money in fiscal 2025: a net loss of $259 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments408305424725519
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio24.9x17.1x13.9x18.9x10.5x
Quick ratio24.9x17.1x13.9x18.9x10.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Celldex Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Celldex Therapeutics shares on the open market, and 1 insider sold $121,231.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Dec 4, 2025Freddy A. JimenezSVP & General CounselSold4,166$29.10$121,231Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−1,393.2%−2,272.9%−13,907.0%
Altman Z''5.9915.111.90
Accruals ratio−8.3%−0.0%−7.0%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin roseFailPassFail
Revenue rose relative to assetsPassFailFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Celldex Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Celldex TherapeuticsFY25−78.0%−18,599.8%−13,829.1%———
Z SquaredFY25—−956.9%————Compare
Inhibrx BiosciencesFY25550.0%−10,386.5%−9,986.5%——2Compare
Shattuck LabsFY25−82.5%−5,150.8%−3,995.3%———Compare
AbsciFY25−38.2%−4,297.0%−3,358.3%−162.8%—3Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue713104752772
Revenue growth23.8%87.8%−25.1%−62.5%107.6%−37.3%−49.3%192.0%2.0%−78.0%
Gross profit51294752771
Research and development103966643425382118164245
Operating income−133−122−156−55−63−71−115−154−195−287
Net income−128−93−151−51−60−70−112−141−158−259
Diluted EPS (US$)−18.99−10.86−14.48−3.51−2.02−1.64−2.40−2.92−2.45−3.90
Diluted shares (millions)791014000486466
Cash flow
Cash from operations−113−100−75−46−40−61−104−107−158−211
Capital expenditure3211212223
Free cash flow−116−102−76−47−42−62−106−109−160−214
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation1512854916243436
Balance sheet at fiscal year end
Cash and short-term investments1901399464194408305424725519
Debt incl. finance leases——————————
Total assets383316156123236445353466792583
Total liabilities118793229262526364556
Shareholders' equity26523612494209420326429747527
Margins and ratios
Gross margin76.4%94.5%92.7%97.2%97.3%97.8%95.8%95.6%97.2%87.1%
Operating margin−1,958.7%−953.7%−1,640.1%−1,540.2%−854.1%−1,531.8%−4,889.0%−2,245.3%−2,778.9%−18,599.8%
Net margin−1,894.0%−730.1%−1,585.1%−1,424.0%−805.9%−1,516.0%−4,765.6%−2,054.8%−2,248.8%−16,748.0%
Free cash flow margin−1,706.3%−798.2%−797.3%−1,319.5%−565.6%−1,336.4%−4,478.6%−1,585.2%−2,274.9%−13,829.1%
Rule of 40 (growth + FCF margin)−1,682.4%−710.5%−822.5%−1,382.0%−458.0%−1,373.7%−4,527.9%−1,393.2%−2,272.9%−13,907.0%
Return on capital——————————
Return on equity−46.3%−37.1%−83.9%−46.7%−39.4%−22.4%−30.1%−37.5%−26.8%−40.6%
Return on assets−35.7%−26.6%−64.1%−36.5%−33.3%−20.7%−28.2%−34.6%−25.1%−37.6%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Celldex Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Celldex Therapeutics.